AVPR1B Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | OPA115268-Each-of-1 | In Stock | ₹ 51,397.50 |
OPA115268 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 51,397.50
GST (18%): ₹ 9,251.55
Total Price: ₹ 60,649.05
Antigen
AVPR1B
Classification
Polyclonal
Conjugate
Unconjugated
Gene
AVPR1B
Gene Alias
Antidiuretic hormone receptor 1b; arginine vasopressin receptor 1B; arginine vasopressin receptor 3; arginine vasopressin receptor V3; arginine vasopressin type 1b receptor; AVP receptor V3; AVPR V1b; AVPR V3; Avpr1b; AVPR3; pituitary vasopressin receptor 3; V1b receptor; V1bR; V3/V1b; V3/V1b pituitary vasopressin receptor; vasopressin V1b receptor; Vasopressin V3 receptor; VIBR; VPR3
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
553
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
Immunohistochemistry (Paraffin)
Concentration
1 mg/mL
Formulation
PBS with 0.1% sodium azide
Gene Accession No.
P47901
Gene Symbols
AVPR1B
Immunogen
Synthetic 17 amino acid peptide from N-terminal extracellular domain of human AVPR1B.
Quantity
25 μg
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- OPA1-15268 detects V1B from human samples
- Vasopressin V1B receptor expression has been documented in the pituitary, pituitary tumors, pheochromocytoma, breast cancer, and small-cell lung carcinomas
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This turn-off activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.